Finerenone is a Small Molecule owned by Bayer, and is involved in 46 clinical trials, of which 36 were completed, 6 are ongoing, and 4 are planned.
Finerenone (BAY-948862) is a mineralocorticoid receptor (MR, aldosterone) antagonist. Aldosterone inhibitors act as diuretics and lowers blood pressure by preventing reab-sorption of salts, reducing blood volume, and antagonizing the action of aldosterone, a component of the renin-angiotensin-aldosterone system (renin-angiotensin-aldosterone system). They inhibit the binding of aldosterone to mineralocorticoid receptors in both epithelial and nonepithelial tissues. In the distal convoluted renal tubule, they promote diuresis and reduce potassium excretion and inhibits aldosterone. Aldosterone inhibitors reduce the swelling and water build-up caused by heart failure.
The revenue for Finerenone is expected to reach a total of $11.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Finerenone NPV Report.
Finerenone is originated and owned by Bayer.
Finerenone (Kerendia) is a nonsteroidal mineralocorticoid. It is formulated as film coated tablets for oral route of administration. Kerendia is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes. Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. Kerendia is indicated for the treatment of chronic kidney disease with type 2 diabetes in adults, excluding patients with end-stage renal disease or on dialysis. Kerendia is indicated for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in adults, to reduce the risk of sustained eGFR decline and end-stage kidney disease.
Finerenone (BAY-948862) is under development for the treatment of diabetic nephropathy, diabetic retinopathy, chronic heart failure and chronic kidney disease, proteinuria, glomerulonephritis, hypertension in patients with type 2 diabetes. The drug candidate is administered orally as a tablet. It is a new molecular entity and acts by targeting non-steroidal mineralocorticoid receptor (MR).
It was under development for the treatment of Duchenne muscular dystrophy.
Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
The company reported revenues of (Euro) EUR44,081 million for the fiscal year ended December 2021 (FY2021), an increase of 6.5% over FY2020. The operating profit of the company was EUR3,353 million in FY2021, compared to an operating loss of EUR16,169 million in FY2020. The net profit of the company was EUR1,000 million in FY2021, compared to a net loss of EUR10,495 million in FY2020. The company reported revenues of EUR11,281 million for the third quarter ended September 2022, a decrease of 12% over the previous quarter.
Quick View – Finerenone
|Highest Development Stage|